改善精神分裂症认知功能的测量与治疗研究：美国国立精神卫生研究所（NIMH）的MATRICS计划，旨在支持开发改善精神分裂症认知功能的药物。

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

作者信息

Marder Stephen R, Fenton Wayne

机构信息

UCLA Neuropsychiatric Institute and the VISN 22 Mental Illness Research, Education, and Clinical Center, MIRECC/210A, West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA.

出版信息

Schizophr Res. 2004 Dec 15;72(1):5-9. doi: 10.1016/j.schres.2004.09.010.

DOI:10.1016/j.schres.2004.09.010

PMID:15531402

Abstract

The impairments in social and vocational outcome that are common in schizophrenia are strongly related to the severity of impaired neurocognition. This observation led to the initiation of The NIMH's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which supports the development of pharmacological agents to improve cognition in schizophrenia. MATRICS addresses barriers to drug development through a number of activities, including the development of a consensus battery for measuring cognition in schizophrenia; the development of a consensus regarding the most promising molecular targets that should be the focus of drug development; the use of a joint meeting with representatives from the industry, academia, NIMH, and the U.S. Food and Drug Administration (FDA) to clarify guidelines for the design of clinical trials for cognition enhancing agents; and finally, to assist NIMH in developing its research agenda in this area.

摘要

精神分裂症中常见的社交和职业功能损害与神经认知功能受损的严重程度密切相关。这一观察结果促使美国国立精神卫生研究所（NIMH）发起了“改善精神分裂症认知的测量与治疗研究”（MATRICS）计划，该计划支持开发改善精神分裂症认知的药物制剂。MATRICS通过一系列活动解决药物开发的障碍，包括开发一套用于测量精神分裂症认知的共识性测试组合；就最有前景的应成为药物开发重点的分子靶点达成共识；与行业、学术界、NIMH和美国食品药品监督管理局（FDA）的代表举行联席会议，以明确认知增强剂临床试验设计的指导原则；最后，协助NIMH制定该领域的研究议程。